Sarepta Therapeutics (SRPT) Operating Margin (2017 - 2025)
Historic Operating Margin for Sarepta Therapeutics (SRPT) over the last 12 years, with Q2 2025 value amounting to 18.91%.
- Sarepta Therapeutics' Operating Margin rose 191100.0% to 18.91% in Q2 2025 from the same period last year, while for Jun 2025 it was 16.16%, marking a year-over-year increase of 136400.0%. This contributed to the annual value of 11.47% for FY2024, which is 330100.0% up from last year.
- Latest data reveals that Sarepta Therapeutics reported Operating Margin of 18.91% as of Q2 2025, which was up 191100.0% from 24.56% recorded in Q4 2024.
- Sarepta Therapeutics' 5-year Operating Margin high stood at 24.56% for Q4 2024, and its period low was 103.36% during Q1 2021.
- Moreover, its 5-year median value for Operating Margin was 41.21% (2022), whereas its average is 32.67%.
- Per our database at Business Quant, Sarepta Therapeutics' Operating Margin soared by 770400bps in 2021 and then crashed by -388500bps in 2022.
- Over the past 5 years, Sarepta Therapeutics' Operating Margin (Quarter) stood at 52.52% in 2021, then grew by 21bps to 41.34% in 2022, then skyrocketed by 115bps to 6.21% in 2023, then skyrocketed by 296bps to 24.56% in 2024, then decreased by -23bps to 18.91% in 2025.
- Its last three reported values are 18.91% in Q2 2025, 24.56% for Q4 2024, and 4.75% during Q3 2024.